BDTX · Categories · Form 4

BDTX - SEC Form 4 insider transactions

Black Diamond Therapeutics Inc. (BDTX) sec form 4 insider transactions - real-time wire coverage filtered to Form 4 only.

Recent Form 4 for BDTX

• 76d
  SEC Form 4 filed by Behbahani Ali

  4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)
• 76d
  SEC Form 4 filed by Raman Prakash

  4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)
• 132d
  SEC Form 4 filed by Officer Jones Erika

  4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)
• 132d
  SEC Form 4 filed by Officer Hatzis-Schoch Brent

  4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)
• 132d
  SEC Form 4 filed by CHIEF MEDICAL OFFICER Yurasov Sergey

  4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)
• 132d
  SEC Form 4 filed by PRESIDENT & CEO Velleca Mark A.

  4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)
• 132d
  SEC Form 4 filed by CHIEF SCIENTIFIC OFFICER Buck Elizabeth

  4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)
• 171d
  Director Behbahani Ali was granted 5,208 shares, increasing direct ownership by 6% to 86,649 units (SEC Form 4)

  4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)
• 171d
  Director Raman Prakash was granted 4,665 shares, increasing direct ownership by 18% to 31,027 units (SEC Form 4)

  4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)
• 255d
  Director Behbahani Ali was granted 4,291 shares, increasing direct ownership by 6% to 81,441 units (SEC Form 4)

  4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)
• 255d
  Director Raman Prakash was granted 3,843 shares, increasing direct ownership by 17% to 26,362 units (SEC Form 4)

  4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)
• 349d
  Director Behbahani Ali was granted 6,170 shares, increasing direct ownership by 9% to 77,150 units (SEC Form 4)

  4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)
• 349d
  Director Raman Prakash was granted 5,526 shares, increasing direct ownership by 33% to 22,519 units (SEC Form 4)

  4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)
• 357d
  SEC Form 4 filed by Director Behbahani Ali

  4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)
• 357d
  SEC Form 4 filed by Director Menzel Garry E

  4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)
• 357d
  SEC Form 4 filed by Director Raman Prakash

  4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)
• 357d
  SEC Form 4 filed by Director Campbell Shannon

  4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)
• 357d
  SEC Form 4 filed by Director Dhingra Kapil

  4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)
• 357d
  SEC Form 4 filed by Director Kulkarni Samarth

  4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)
• 440d
  Director Behbahani Ali was granted 7,646 shares, increasing direct ownership by 12% to 70,980 units (SEC Form 4)

  4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)
• 440d
  Director Raman Prakash was granted 6,848 shares, increasing direct ownership by 68% to 16,993 units (SEC Form 4)

  4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)
• 441d
  Large owner Biotech Growth N V sold $11,997,749 worth of shares (5,784,292 units at $2.07), decreasing direct ownership by 68% to 2,733,547 units (SEC Form 4)

  4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)
• 489d
  PRESIDENT & CEO Velleca Mark A. was granted 75,000 shares, increasing direct ownership by 161% to 121,522 units (SEC Form 4)

  4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)
• 489d
  CHIEF MEDICAL OFFICER Yurasov Sergey was granted 75,000 shares (SEC Form 4)

  4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)
• 489d
  CHIEF SCIENTIFIC OFFICER Buck Elizabeth was granted 75,000 shares, increasing direct ownership by 79% to 170,192 units (SEC Form 4)

  4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)
• 489d
  Officer Jones Erika was granted 75,000 shares, increasing direct ownership by 739% to 85,150 units (SEC Form 4)

  4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)
• 489d
  Officer Hatzis-Schoch Brent was granted 75,000 shares, increasing direct ownership by 893% to 83,400 units (SEC Form 4)

  4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)
• 535d
  Director Behbahani Ali was granted 5,750 shares, increasing direct ownership by 10% to 63,334 units (SEC Form 4)

  4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)
• 535d
  Director Raman Prakash was granted 5,150 shares, increasing direct ownership by 103% to 10,145 units (SEC Form 4)

  4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)
• 535d
  Director Campbell Shannon was granted 4,500 shares, increasing direct ownership by 103% to 8,865 units (SEC Form 4)

  4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)
• 622d
  Director Behbahani Ali was granted 3,007 shares, increasing direct ownership by 6% to 57,584 units (SEC Form 4)

  4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)
• 622d
  Director Campbell Shannon was granted 2,354 shares, increasing direct ownership by 117% to 4,365 units (SEC Form 4)

  4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)
• 622d
  Director Raman Prakash was granted 2,694 shares, increasing direct ownership by 117% to 4,995 units (SEC Form 4)

  4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)
• 643d
  Large owner Versant Venture Capital Vi, L.P. sold $1,400,556 worth of shares (221,600 units at $6.32) (SEC Form 4)

  4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)
• 713d
  Director Behbahani Ali was granted 2,887 shares, increasing direct ownership by 6% to 54,577 units (SEC Form 4)

  4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)
• 713d
  Director Raman Prakash was granted 2,301 shares (SEC Form 4)

  4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)
• 713d
  Director Campbell Shannon was granted 2,011 shares (SEC Form 4)

  4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)
• 728d
  SEC Form 4 filed by Behbahani Ali

  4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)
• 728d
  SEC Form 4 filed by Kulkarni Samarth

  4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)
• 728d
  SEC Form 4 filed by Menzel Garry E

  4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)
• 728d
  SEC Form 4 filed by Raman Prakash

  4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)
• 728d
  SEC Form 4 filed by Campbell Shannon

  4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)
• 728d
  SEC Form 4 filed by Dhingra Kapil

  4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)
• 783d
  SEC Form 4 filed by Campbell Shannon

  4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)
• 783d
  SEC Form 4 filed by Raman Prakash

  4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)
• 792d
  Behbahani Ali was granted 3,166 shares, increasing direct ownership by 7% to 51,690 units (SEC Form 4)

  4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)
• 792d
  Dixon Wendy L was granted 3,253 shares, increasing direct ownership by 9% to 38,054 units (SEC Form 4)

  4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)
• 840d
  SEC Form 4 filed by Ni Fang

  4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)
• 840d
  SEC Form 4 filed by Hatzis-Schoch Brent

  4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)
• 840d
  SEC Form 4 filed by Yurasov Sergey

  4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)
• 840d
  SEC Form 4 filed by Buck Elizabeth

  4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)
• 840d
  SEC Form 4 filed by Velleca Mark A.

  4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)
• 840d
  SEC Form 4 filed by Jones Erika

  4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)
• 902d
  Behbahani Ali was granted 4,455 shares, increasing direct ownership by 10% to 48,524 units (SEC Form 4)

  4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)
• 902d
  Dixon Wendy L was granted 4,043 shares, increasing direct ownership by 13% to 34,801 units (SEC Form 4)

  4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)
• 990d
  SEC Form 4: Behbahani Ali was granted 3,299 shares, increasing direct ownership by 8% to 44,069 units

  4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)
• 990d
  SEC Form 4: Velleca Mark A. was granted 5,208 shares, increasing direct ownership by 13% to 46,522 units

  4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)
• 990d
  SEC Form 4: Dixon Wendy L was granted 2,986 shares, increasing direct ownership by 11% to 30,758 units

  4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)
• 1063d
  SEC Form 4 filed by Ra Capital Management, L.P.

  4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)
• 1064d
  SEC Form 4 filed by Behbahani Ali

  4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)

Other BDTX categories

• 8-K
• 10-K
• 10-Q
• S-1
• 13D
• 13G
• Form 3
• Form 5
• DEF 14A
• M&A
• Earnings
• Dividends